Diuretics in Heart Failure. Practical Considerations

Medical Clinics of North America

Volumn 96, Issue 5, 2012, Pages 933-942

  Basraon, Jagroop ^a   Deedwani, Prakash C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cardiology Division   (United States)

Author keywords

Diuretic resistance; Diuretics; Heart failure; Loop diuretics

Indexed keywords

ALDOSTERONE; BUMETANIDE; CALCIUM; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; MAGNESIUM; METOLAZONE; MINERALOCORTICOID RECEPTOR ANTAGONIST; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; UNCLASSIFIED DRUG; URIC ACID;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ANEMIA; BLOOD PRESSURE; CARDIORENAL SYNDROME; COMORBIDITY; DEHYDRATION; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TARGETING; ELECTROLYTE TRANSPORT; ENDOTHELIAL DYSFUNCTION; FLUID INTAKE; FLUID RETENTION; GOUT; HEART FAILURE; HENLE LOOP; HUMAN; HYPERALDOSTERONISM; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY COLLECTING TUBULE; KIDNEY DISEASE; KIDNEY DISTAL TUBULE; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY PERFUSION; LIVER DISEASE; LIVER METABOLISM; NEPHRON; OTOTOXICITY; OXIDATIVE STRESS; PARACENTESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC TONE; TREATMENT RESPONSE; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIO-RENAL SYNDROME; DIURETICS; HEART FAILURE; HUMANS;

EID: 84866170663     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.07.003     Document Type: Review

References (36)

1. Vargo D.L., Kramer W.G., Black P.K., et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995, 57(6):601-609.
2. Brater D.C., Leinfelder J., Anderson S.A. Clinical pharmacology of torsemide, a new loop diuretic. Clin Pharmacol Ther 1987, 42(2):187-192.
3. Brater D.C., Chennavasin P., Day B., et al. Bumetanide and furosemide. Clin Pharmacol Ther 1983, 34(2):207-213.
4. Welling P.G. Pharmacokinetics of the thiazide diuretics. Biopharm Drug Dispos 1986, 7(6):501-535.
5. Beermann B., Groschinsky-Grind M., Rosen A. Absorption, metabolism, and excretion of hydrochlorothiazide. Clin Pharmacol Ther 1976, 19(5 Pt 1):531-537.
6. Huang C.M., Atkinson A.J., Levin M., et al. Pharmacokinetics of furosemide in advanced renal failure. Clin Pharmacol Ther 1974, 16(4):659-666.
7. Hou W., Sanyal A.J. Ascites: diagnosis and management. Med Clin North Am 2009, 93(4):801-817. vii.
8. Fuller R., Hoppel C., Ingalls S.T. Furosemide kinetics in patients with hepatic cirrhosis with ascites. Clin Pharmacol Ther 1981, 30(4):461-467.
9. Villeneuve J.P., Verbeeck R.K., Wilkinson G.R., et al. Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther 1986, 40(1):14-20.
10. Chennavasin P., Seiwell R., Brater D.C. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther 1980, 215(1):77-81.
11. Chennavasin P., Seiwell R., Brater D.C., et al. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979, 16(2):187-195.
12. Cook J.A., Smith D.E., Cornish L.A., et al. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure. Clin Pharmacol Ther 1988, 44(5):487-500.
13. Brater D.C. Diuretic therapy. N Engl J Med 1998, 339(6):387-395.
14. Mielniczuk L.M., Tsang S.W., Desai A.S., et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 2008, 14(5):388-393.
15. Thomson M.R., Nappi J.M., Dunn S.P., et al. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail 2010, 16(3):188-193.
16. Dormans T.P., van Meyel J.J., Gerlag P.G., et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996, 28(2):376-382.
17. Allen L.A., Turer A.T., Dewald T., et al. Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol 2010, 105(12):1794-1797.
18. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011, 364(9):797-805.
19. Sica D.A. Metolazone and its role in edema management. Congest Heart Fail 2003, 9(2):100-105.
20. Ghose R.R., Gupta S.K. Synergistic action of metolazone with "loop" diuretics. Br Med J (Clin Res Ed) 1981, 282(6274):1432-1433.
21. Brater D.C., Pressley R.H., Anderson S.A. Mechanisms of the synergistic combination of metolazone and bumetanide. J Pharmacol Exp Ther 1985, 233(1):70-74.
22. Jentzer J.C., DeWald T.A., Hernandez A.F. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010, 56(19):1527-1534.
23. Cooper H.A., Dries D.L., Davis C.E., et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100(12):1311-1315.
24. Stanton B.A., Kaissling B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am J Physiol 1988, 255(6 Pt 2):F1269-F1275.
25. Kobayashi S., Clemmons D.R., Nogami H., et al. Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1. Kidney Int 1995, 47(3):818-828.
26. Greenberg A. Diuretic complications. Am J Med Sci 2000, 319(1):10-24.
27. Tannen R.L. Diuretic-induced hypokalemia. Kidney Int 1985, 28(6):988-1000.
28. Helgeland A., Hjermann I., Holme I., et al. Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The Oslo study. Am J Med 1978, 64(1):34-38.
29. Johnson M.W., Mitch W.E. The risks of asymptomatic hyperuricaemia and the use of uricosuric diuretics. Drugs 1981, 21(3):220-225.
30. Klein L., O'Connor C.M., Leimberger J.D., et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005, 111(19):2454-2460.
31. Bock J.S., Gottlieb S.S. Cardiorenal syndrome: new perspectives. Circulation 2010, 121(23):2592-2600.
32. Brilla C.G., Pick R., Tan L.B., et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circulation 1990, 67(6):1355-1364.
33. Vesey D.A., Cheung C., Pat B., et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004, 19(2):348-355.
34. Tojo A., Onozato M.L., Kobayashi N., et al. Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure. Hypertension 2002, 40(6):834-839.
35. Gheorghiade M., Abraham W.T., Albert N.M., et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007, 28(8):980-988.
36. Schrier R.W., Gross P., Gheorghiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355(20):2099-2112.